73 results on '"Lin, Chen-Yen"'
Search Results
2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
3. Reweighting estimators to extend the external validity of clinical trials: methodological considerations
4. Efficient survivable mapping algorithm for logical topology in IP-over-WDM optical networks against node failure
5. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
6. P276 Ixekizumab shows a pattern of pain improvement in patients with and without measurable inflammation in psoriatic arthritis
7. Value of PASI90 Versus Merit-Based Incentive Payment System Efficacy Measures
8. Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathways
9. Rapid and sustained improvements in patient-reported signs and symptoms with ixekizumab in biologic-naive and TNF-inadequate responder patients with psoriatic arthritis
10. Approaches to illuminate content-specific gameplay decisions using open-ended game data
11. On the design and the analysis of stratified biomarker trials in the presence of measurement error
12. A comparison of reweighting estimators of average treatment effects in real world populations
13. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies
14. Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors
15. Disease response and patient-reported outcomes among initiators of ixekizumab
16. Telecentric design for digital‐scanning‐based HiLo optical sectioning endomicroscopy with an electrically tunable lens
17. Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 Studies
18. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
19. Ixekizumab, With Or Without Concomitant Methotrexate, Improves Signs And Symptoms Of Psa: Week 52 Results From Spirit-P1 And Spirit-P2 Studies
20. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis
21. Fluorescence sectioning micro-endoscopy using hybrid illumination
22. Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient’s perspective
23. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
24. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
25. Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
26. Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
27. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab
28. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis
29. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis
30. SAT0374 IXEKIZUMAB, WITH OR WITHOUT CONCOMITANT METHOTREXATE, IMPROVES THE SIGNS AND SYMPTOMS OF PSA FOR UP TO 52 WEEKS OF TREATMENT
31. FRI0430 IXEKIZUMAB IMPROVES THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS REGARDLESS OF SEX, DURATION OF DISEASE, OR BODY MASS INDEX IN TWO RANDOMIZED, PHASE 3 CLINICAL TRIALS
32. OP0110 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO 1 OR 2 TUMOR NECROSIS FACTOR INHIBITORS
33. SAT0396 IMPROVEMENT IN THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS WITH IXEKIZUMAB COMPARED TO PLACEBO IN PATIENT SUBGROUPS DEFINED BY BASELINE DISEASE CHARACTERISTICS
34. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire
35. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
36. Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma Cells
37. Ixekizumab Improved Patient-Reported Genital Psoriasis Symptoms and Impact of Symptoms on Sexual Activity vs Placebo in a Randomized, Double-Blind Study
38. Prototype Filter Design in GFDM Systems in Presence of PA Nonlinearity
39. Simultaneous multiplane imaging with programmable multiplexed gratings
40. Speckle illumination holographic non-scanning fluorescence endoscopy
41. Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
42. Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)
43. Non-scanning in-vivo three-dimensional hybrid structured illumination microscopy
44. Edge contrast enhancement at multiple planes using forked shaped defocus grating
45. Multi-focal imaging system by using a programmable spatial light modulator
46. Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
47. Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis
48. Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
49. Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
50. Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.